DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy

Inclusion Criteria: * Female/male of at least 40 years of age * Patient diagnosed with COPD * Patient was changed over within the last 3 months to a fixed-dose combination (FDC) (Aclidinium/Formeterol, Glycopyrronium/Indacaterol or Umeclidinium/Vilanterol), or there is already the intent to change the patient over to a fixed-dose combination (Aclidinium/Formeterol, Glycopyrronium/Indacaterol or Umeclidinium/Vilanterol). * Lung function parameters and CAT score from the time prior to the changeover to an FDC are on record (within the last 6 months in the case of patients who have already been changed over) or are determined at the 1st visit (in the case of patients who have not yet been changed over but for whom such a changeover is intended). * Signed declaration of consent Exclusion Criteria: * The prescribing information for the fixed-dose combinations (Duaklir® Genuair®, Ulibtro® Breezhaler® or Anoro®) list contraindications for the patient. * Patient is pregnant, plans to become pregnant, or is nursing during the therapy period. * Patient suffers from hypersensitivity to one of the active ingredients of the fixed-dose combinations. * Patient is participating in a clinical trial.